ACM
NBIX icon

Ascendant Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Ascendant Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,000
Closed -$358K – 74
2022
Q4 		$358K Buy
+3,000
New +$351K 1.07% 38

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ascendant Capital Management's NBIX Position: Q1 2023 in Review

Ascendant Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2023, closing a stake of 3,000 shares — an estimated $358K sold.

Ascendant Capital Management first reported a position in NBIX in Q4 2022 and held it in 1 quarter. The position peaked at $358K in Q4 2022. 486 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.

  • Ascendant Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2023 after selling out during the quarter.
  • Ascendant Capital Management sold 3,000 Neurocrine Biosciences shares in Q1 2023, an estimated $358K.
  • Ascendant Capital Management first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 1 quarter.
  • Ascendant Capital Management's Neurocrine Biosciences position peaked at $358K in Q4 2022.
  • 486 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.

Based on Ascendant Capital Management's 13F filing for Q1 2023, filed 15 May 2023.